Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Preferred Shares (2021 - 2025)

PAVmed has reported Preferred Shares over the past 5 years, most recently at $3.7 million for Q4 2025.

  • Quarterly results put Preferred Shares at $3.7 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $3.7 million (changed N/A YoY), and the annual figure for FY2025 was $3.7 million, changed.
  • Preferred Shares for Q4 2025 was $3.7 million at PAVmed, up from $3.6 million in the prior quarter.
  • Over the last five years, Preferred Shares for PAVM hit a ceiling of $3.7 million in Q4 2025 and a floor of $2.4 million in Q3 2021.
  • Median Preferred Shares over the past 5 years was $2.8 million (2023), compared with a mean of $2.9 million.
  • Peak annual rise in Preferred Shares hit 11.56% in 2022, while the deepest fall reached 3.9% in 2022.
  • PAVmed's Preferred Shares stood at $2.4 million in 2021, then increased by 11.41% to $2.7 million in 2022, then rose by 11.06% to $3.0 million in 2023, then rose by 5.28% to $3.2 million in 2024, then increased by 16.31% to $3.7 million in 2025.
  • The last three reported values for Preferred Shares were $3.7 million (Q4 2025), $3.6 million (Q3 2025), and $3.5 million (Q2 2025) per Business Quant data.